Raphael Pharmaceutical Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Raphael Pharmaceutical Inc. has filed its 2023 10-K annual report, detailing its corporate structure and compliance status.</b>

AI Summary

Raphael Pharmaceutical Inc. (RAPH) filed a Annual Report (10-K) with the SEC on March 28, 2024. Raphael Pharmaceutical Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Nevada and its principal executive offices are located in Tel Aviv-Jaffa, Israel. Raphael Pharmaceutical Inc. is classified under SIC code 2833 (Medicinal Chemicals & Botanical Products). The company has common stock with a par value of $0.01 registered under Section 12(g) of the Act. Raphael Pharmaceutical Inc. has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Raphael Pharmaceutical Inc., this filing contains several important signals. This filing provides a comprehensive overview of Raphael Pharmaceutical Inc.'s financial and operational status for the fiscal year 2023, crucial for investors assessing the company's performance and outlook. As a smaller reporting company, this 10-K is essential for understanding Raphael Pharmaceutical Inc.'s regulatory compliance and its position within the medicinal chemicals and botanical products industry.

Risk Assessment

Risk Level: low — Raphael Pharmaceutical Inc. shows low risk based on this filing. The filing is a standard 10-K for a smaller reporting company, indicating no immediate high-risk financial or operational disclosures beyond typical annual reporting requirements.

Analyst Insight

Investors should review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to form an investment thesis.

Key Numbers

• 2023 — Fiscal Year End (Fiscal year ended December 31, 2023)
• 2833 — SIC Code (Standard Industrial Classification: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS)
• 000-53002 — Commission File Number (Commission File No.)
• 0001213900-24-027234 — Accession Number (Accession Number)

Key Players & Entities

• Raphael Pharmaceutical Inc. (company) — Registrant name
• 2023 (date) — Fiscal year end
• December 31, 2023 (date) — Fiscal year end
• Nevada (jurisdiction) — State of incorporation
• Tel Aviv-Jaffa, Israel (location) — Address of Principal Executive Offices
• 2833 (sic_code) — Standard Industrial Classification
• 000-53002 (filing_number) — Commission File Number
• 0001213900-24-027234 (accession_number) — Accession Number

FAQ

Industry Context

Raphael Pharmaceutical Inc. operates within the Medicinal Chemicals & Botanical Products industry, as indicated by its SIC code 2833.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, as evidenced by its filing of a Form 10-K.

What Investors Should Do

1. Review the full 10-K for detailed financial performance and operational disclosures.
2. Analyze the company's risk factors section for potential investment concerns.
3. Compare Raphael Pharmaceutical Inc.'s SIC code 2833 classification with industry peers.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-03-28: Filing Date — Date the 10-K report was filed with the SEC.

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year 2023, providing a baseline for future comparisons.

Key Financial Figures

• $0.01 — ction 12(g) of the Act: Common Stock, $0.01 par value (Title of class) Indicate
• $1 — 0,016,986 based on the closing price of $1 per share of the registrant's common st
• $0 — 1,418 shares of common stock, par value $0.01, or Common Stock, of the registrant

Filing Documents

• ea0202331-10k_raphael.htm (10-K) — 1345KB
• ea020233101ex10-4_raphael.htm (EX-10.4) — 3KB
• ea020233101ex31-1_raphael.htm (EX-31.1) — 10KB
• ea020233101ex31-2_raphael.htm (EX-31.2) — 10KB
• ea020233101ex32-1_raphael.htm (EX-32.1) — 3KB
• ea020233101ex32-2_raphael.htm (EX-32.2) — 3KB
• image_001.jpg (GRAPHIC) — 11KB
• image_002.jpg (GRAPHIC) — 23KB
• image_003.jpg (GRAPHIC) — 3KB
• image_004.jpg (GRAPHIC) — 28KB
• 0001213900-24-027234.txt (&nbsp;) — 4409KB
• raph-20231231.xsd (EX-101.SCH) — 43KB
• raph-20231231_cal.xml (EX-101.CAL) — 28KB
• raph-20231231_def.xml (EX-101.DEF) — 157KB
• raph-20231231_lab.xml (EX-101.LAB) — 282KB
• raph-20231231_pre.xml (EX-101.PRE) — 148KB
• ea0202331-10k_raphael_htm.xml (XML) — 301KB

Business

Business 1 Item 1A. Risk Factors 24 Item 1B. Unresolved Staff Comments 51 Item 1C Cyber Security 51 Item 2.

Properties

Properties 51 Item 3. Legal Proceedings 51 Item 4. Mine Safety Disclosures 51 PART II 52 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 52 Item 6. [Reserved] 52 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 52 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 58 Item 8. Financial 58 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 58 Item 9A. Controls and Procedures 59 Item 9B. Other Information 59 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 59 PART III 60 Item 10. Directors, Executive Officers and Corporate Governance 60 Item 11. Executive Compensation 62 Item 12. Security 64 Item 13. Certain Relationships and Related Transactions, and Director Independence 65 Item 14. Principal Accounting Fees and Services 67 PART IV 68 Item 15. Exhibits and Financial Statement Schedules 68 Item 16. Form 10-K Summary 69

Signatures

Signatures 69 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (the "Annual Report"), contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, which includes information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, identify forward-looking of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking the regulatory pathways that we may elect to utilize in seeking U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and other regulatory approvals, if any; obtaining (and the cost thereof) FDA and EMA approval of, or other regulatory action in Europe or the United States and elsewhere with respect to our product candidates; the commercial launch and future sales of our product candidates and our advancement of product candidates for other indications in our pipeline; the potential cost of our rheumatoid arthritis product candidate, or RA and RA product candidate, respectively, for patients; our expecta

View Full Filing

View this 10-K filing on SEC EDGAR